A00-250 study tips - SAS Platform Administration for SAS9 Updated: 2023

Do you want to develop your academic study skills?

Get the study tips and knowledge you need for distance learning success with our Go The Distance course.

Watch our Study Skills series – our fun animated videos will help develop your study skills, whether or not you're a distance learner. subjects include: quoting, paraphrasing and summarising; critical thinking skills; listening and note-taking and more.

Click on the images and get the knowledge!

Many students carry out a project (internship or student research project) at an institution outside ETH.

In some cases, it is possible for students to do their project through an exchange programme. There are exchange agreements with all Swiss and many European universities, which include stays for projects.

For internships and other projects/study work outside of Switzerland, there are funding opportunities such as SEMP Europe Projects & Internships and SEMP Worldwide Projects & Internships. These are not linked to exchange agreements and all institutions (companies, research institutions, universities) are open.

Please refer students to us or to our website as early as possible so that we can clarify whether one of the programmes is an option.

The students organise the projects independently. However, all projects must be agreed with the department. The main supervision of student research projects always lies with ETH, even if they are carried out externally. Internships must be approved by the person responsible for the internship in the department (only compulsory or recommended internships).

Benefits of Massey's MBA

Massey’s MBA is unique in New Zealand – the only MBA with specialisations offered part-time fully online or full-time in a year.

Gain practical knowledge you can use immediately at work. You will benefit from connection to practice through engagement with business leaders and assignments that often include corporate consultancy work.

Our MBA has no examinations, and all assessments are practical.

Learn about how you can expand your opportunities with our internationally accredited MBA

Study with us online

Our flexible and convenient fully-online MBA can be completed from anywhere in New Zealand or worldwide. With scheduled small group interactive sessions and on-call support, you'll be able to manage your workload while staying connected to support.

Massey is an expert in distance learning, with fresh material often contributed by managers from businesses in NZ and globally.

Study with us on campus

This practical learning approach allows you to study full-time and complete your studies within a year.

Our face-to-face class sessions are in the afternoon from Tuesday to Thursday in Auckland. You'll have ample opportunities to work part-time and remain current with practical job skills.

Our people

Meet your MBA practitioner academics.

Professor Dr Dr Jens Mueller

MNZM, PhD, MSAM, LLM, JurDr, MBA, GDNZIA, GD ProfCoach, MRSNZ

Professor of Management Practice, Massey Executive Development Director

Jens has been a CEO and Director in global firms, including more than 9 years as Board Director for the $1+ Billion PHARMAC Crown entity, an advisor to Governments and corporate leaders and is also a Licensed Immigration Adviser.

Flavio Hangarter

MMgt

Lecturer and Growth/Innovation Consultant

Flavio is a sought-after advisor for launching and scaling technology companies with 12+ years of experience working with executives, tech accelerators, governments and NGOs across the globe. 

In total you will take eight  courses over a 22-month period. You will attend LSE for five week-long courses, as well as for a 3-day Introduction to Public Policy course, and two 3-day workshops on Policy in Practice. You will customise your learning experience by choosing two specialist modules from a range of options listed below.

You may also like to view the Department's webpages about this programme for further detail.

First year

(* denotes a half unit)

The EMPA does not require you to have a prior knowledge of economics or statistics. At the start of each intake, we deliver a 2-day Introduction to Statistics Workshop.

The workshop, which is not assessed, ensures that you are ready to undertake the EMPA by quickly and effectively bringing you up to the necessary level required to understand the concepts discussed in the courses that follow.

Introduction to Public Policy*
This introductory course provides you with the foundations for analysing key public policy questions. We will introduce how and why to study policy problems and solutions analytically and systematically. You’ll learn how to think about handling situations where there are competing interests and how incentives affect behaviour, and you’ll learn when markets deliver good outcomes and, more importantly, when they don’t, thus justifying intervention or regulation.

Political Science and Public Policy*
This core course introduces you to a range of theoretical and empirical tools to analyse the politics of policy-making. The main focus is on political institutions in modern democracies and how they relate to public policy. subjects include elections, representation, delegation, accountability, interest groups, legislatures, executives, and decentralisation.

Public Policy in Practice Workshop I*
This introductory workshop demonstrates how economists and political scientists approach policy challenges with the aim of encouraging you to start thinking like a social scientist. 

Economic Policy Analysis*
This core course covers both key microeconomic policy issues, such as externalities, public goods and principal-agent problems, and macroeconomic issues such as unemployment, fiscal and monetary policies, international trade and finance, and the determinants of long-run growth. The emphasis is on acquiring sound models and methods suitable for appraising policy-making issues in a wide variety of contexts.

Public Policy in Practice Workshop I*
This workshop applies the analytical tools that are taught in the week-long courses of the EMPA to specific policy areas using an innovative mix of academic thinking and senior practitioner insights.

Second year

Public Policy in Practice Workshop II*
This workshop applies the analytical tools that are taught in the week-long courses of the EMPA to specific policy areas using an innovative mix of academic thinking and senior practitioner insights.

In your second year you also choose two optioncourses, which allow you to specialise in policy areas of particular interest to you. You can also ‘audit’ a 3^rd option course, that is fully participate but not submit assessment. Please note that ‘audit’ courses do not appear transcripts. An indicative list of option courses is listed below:

Global Market Economics*

Public Economics for Public Policy*

Regulatory Analysis*

Fiscal Governance and Budgeting*

Development Economics*

You can find the most up-to-date list of option courses in the Programme Regulations section of the current School Calendar.

You must note, however, that while care has been taken to ensure that this information is up to date and correct, a change of circumstances since publication may cause the School to change, suspend or withdraw a course or programme of study, or change the fees that apply to it. The School will always notify the affected parties as early as practicably possible and propose any viable and relevant alternative options. Note that the School will neither be liable for information that after publication becomes inaccurate or irrelevant, nor for changing, suspending or withdrawing a course or programme of study due to events outside of its control, which includes but is not limited to a lack of demand for a course or programme of study, industrial action, fire, flood or other environmental or physical damage to premises.

You must also note that places are limited on some courses and/or subject to specific entry requirements. The School cannot therefore guarantee you a place. Please note that changes to programmes and courses can sometimes occur after you have accepted your offer of a place. These changes are normally made in light of developments in the discipline or path-breaking research, or on the basis of student feedback. Changes can take the form of altered course content, teaching formats or assessment modes. Any such changes are intended to enhance the student learning experience. You should visit the School’s Calendar, or contact the relevant academic department, for information on the availability and/or content of courses and programmes of study. Certain substantive changes will be listed on the updated graduate course and programme information page.

^{This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021.}

MONTREAL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced results from a study evaluating an intramuscular (IM) method of administration for Trogarzo^® (ibalizumab-uiyk), a monoclonal antibody antiretroviral therapy (ART) for the treatment of heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection failing their current antiretroviral regimen.

The TMB-302 study, conducted in partnership with TaiMed Biologics, enrolled 21 subjects (7 HIV-positive and 14 HIV-negative) to assess the pharmacokinetics, efficacy, and safety of IM administration of Trogarzo^® as compared to intravenous (IV) infusion.

Mean Trogarzo^® trough concentrations were greater than 15 µg/mL, suggesting that IM injection was sufficient at maintaining the drug trough concentration above the therapeutic level of 0.3 µg/mL. The mean trough concentrations were comparable between IV infusion and IM injection in HIV-positive subjects. However, the primary endpoint measuring a 90% confidence interval of the ratio of IM injection to IV infusion (0.69, 1.08) did not meet the equivalence limits (0.8, 1.25). Viral suppression, a key secondary clinical endpoint, was maintained in all HIV-positive subjects throughout the IM phase and the overall study.

Each study subject received IM maintenance doses for eight weeks of treatment and a total of 152 IM injections were administered, which were well tolerated. One subject reported injection-site pruritus (itching) at a single time point, and no subjects reported injection-site pain when Trogarzo^® was administered intramuscularly.

Story continues

With the TMB-302 data in hand, Theratechnologies is seeking expert advice prior to completing a regulatory submission of the Trogarzo^® IM administration maintenance dose to the U.S. Food and Drug Administration (FDA). The FDA is currently reviewing the Company’s submission for the loading dose of the Trogarzo^® IV push method of administration and a decision is expected in mid-December.

About Trogarzo^® (ibalizumab-uiyk)

Trogarzo^® (ibalizumab-uiyk) is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. In the United States, Trogarzo^®, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Trogarzo^® is not approved in Canada.

Trogarzo^® is administered by intravenous infusion as a single loading dose of 2,000 mg followed by a maintenance dose of 800 mg every two weeks after dilution in 250 mL of 0.9% Sodium Chloride Injection, USP. In October 2022, the Trogarzo^® maintenance dose was approved by the FDA to also be administered as an undiluted IV push over 30 seconds.

Important Safety Information

Do not receive Trogarzo^® if you have had an allergic reaction to Trogarzo^® or any of the ingredients in Trogarzo^®. Trogarzo^® can cause allergic reactions, including serious reactions, during and after infusion. Tell your healthcare provider or nurse, or get medical help right away if you experience any symptoms of an allergic reaction. Before you receive Trogarzo^®, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant as it is not known if Trogarzo^® may harm your unborn baby, or if you are breastfeeding or plan to breastfeed as it is not known if Trogarzo^® passes into breast milk. Tell your healthcare provider about all the medicines you take, including all prescription and over-the-counter medicines, vitamins, and herbal supplements.

Changes in your immune system (immune reconstitution inflammatory syndrome) can happen when you start taking HIV-1 medicines. Your immune system might get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you start having new symptoms after starting your HIV-1 medicine. The most common side effects of Trogarzo^® include diarrhea, dizziness, nausea, and rash. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Trogarzo^®. For more information, ask your healthcare provider or pharmacist.

Full prescribing information is available at www.trogarzo.com.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedarplus.ca, and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and Twitter.

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as "may", "will", "should", "could", “promising”, “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the completion of a regulatory submission of the Trogarzo^® IM administration maintenance dose with the FDA and the timelines about expected decision of the FDA on the Company’s submission for the IV push method of administration of the Trogarzo^® loading dose. Certain assumptions made in preparing the Forward-Looking Statements include that: we will file the regulatory submission of the Trogarzo^® IM administration maintenance dose with the FDA in the last calendar quarter of 2023; the FDA will approve the IM administration of Trogarzo^® option for the maintenance dose and the IV push method of administration of the Trogarzo^® loading dose; sales of Trogarzo^® will increase with the addition of those two methods of administration; and Trogarzo^® will continue being reimbursed by private and public payors. Forward-Looking Statements are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to, those related to or arising from: a delay in the filing of the regulatory submission of the Trogarzo^® IM administration maintenance dose to the FDA; the non-filing of the IM administration maintenance dose of Trogarzo^® with the FDA if experts recommend against it; the non-approval by the FDA of the Trogarzo^® IM administration maintenance dose and/or the IV push method of administration of the Trogarzo^® loading dose; and, sales of Trogarzo^® do not increase despite the approval by the FDA of both or any one of those new methods of administration of Trogarzo^® . We refer current and potential investors to the “Risk Factors” section of our Annual Information Form dated February 27, 2023, available on SEDAR at www.sedarplus.ca and on EDGAR at www.sec.gov as an exhibit to our report on Form 40-F dated February 28, 2023, under Theratechnologies’ public filings for additional risks involved in our business. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on Forward-Looking Statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Contacts:

Investor inquiries:
Phillipe Dubuc
Senior Vice President and Chief Financial Officer
pdubuc@theratech.com
438-315-6608

Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
1-514-336-7800

The MBA program at UMass Lowell prepares students to effectively lead organizations in rapidly changing and diverse regional, national and global business environments, and fosters connections with alumni who lead Fortune 500 and innovative start-up companies – as well as everything in between.

Several different options allow students to tailor the MBA program to their career needs, and the program’s flexibility allows students to attend full- or part-time, with online options. 

Our MBA graduates benefit not only from the degree itself, but also from the name of the degree-granting institution – the well-established, AACSB accredited, and highly ranked University of Massachusetts Lowell.

UMass Lowell has a long history in business education, preparing students for current and emerging economic sectors. Close ties to industry have developed, since our first managers were trained to lead the industrial revolution of the 1800s, which began in Lowell. These real-world connections infuse the MBA curriculum, while offering students a wide range of internship experiences and links to future employers. 

Today, UMass Lowell MBA alumni lead companies in the financial, life sciences, high technology and defense sectors, to name just a few. They have also started numerous new ventures. UMass Lowell is a recognized innovation hub, hosting two start-up business incubators. UMass Lowell’s Manning School of Business partners with the Francis College of Engineering and the UMass Medical School to bring new medical device products to market, and the university hosts one of the world’s most respected conferences on entrepreneurialism in higher education.